Engineering HER2-targeted biparatopic antibodies to promote receptor internalization and restore antitumor efficacy
HER2 is a well-established oncogenic driver in breast, gastric, and other solid tumors. While HER2-targeted therapies such as trastuzumab and pertuzumab have improved clinical outcomes, resistance, particularly to trastuzumab, remains a major therapeut…